Fig 1.
Representative micrographs showing the immunohistochemical (IHC) scores of ASS1 expression (on a scale of 0–3) in pancreatic ductal adenocarcinomas.
(A) IHC score 3, (B) IHC score 2, (C) IHC score 1 and (D) IHC score 0.
Fig 2.
The average immunohistochemical scores of ASS1 expression is significantly lower in treated cohort than that in untreated cohort (p = 0.007).
Fig 3.
Representative micrographs showing ASS1 expression in normal pancreas (A) and chronic pancreatitis tissue (B).
Table 1.
Correlation of ASS1 Expression and Clinicopathologic Parameters in Untreated Group and Treated Groups.
Fig 4.
Kaplan–Meier survival curves showing that low ASS1 expression (ASS1-low) is associated reduced overall survival (p = 0.005, A) and disease-free survival (p = 0.001, B) compared to those whose tumors are ASS1-high in the untreated cohort. (C) and (D) Kaplan–Meier survival curves showing that ASS1-low is associated reduced overall survival (p = 0.04, C), but not disease-free survival (p = 0.13, D) compared to those whose tumors are ASS1-high in the treated cohort.
Table 2.
Univariate Cox Regression Analysis of Disease-free and Overall Survival in Untreated Group.
Table 3.
Multivariate Cox Regression Analysis of Disease-free and Overall Survival in Untreated Group.
Table 4.
Univariate Cox Regression Analysis of Overall Survival in Treated Group.
Table 5.
Multivariate Cox Regression Analysis of Overall Survival in Treated Group.